| abstract |
Described herein are methods for identifying a subgroup of ovarian cancer patients that can be responsive to treatment regimens that target folate receptor alpha (FRA) expressing ovarian tumors, and anti-FRA therapeutics (eg, specific for FRA Disclosed is a method for treating a patient using an antigen binding protein (eg, an antibody or antigen binding fragment thereof) that binds selectively. Also disclosed are related kits for identifying and treating the ovarian cancer patient subgroup. [Selection] Figure 1 |